Futura Medical PLC has confirmed that its lead product, Eroxon, will be available on prescription in England and Wales for the treatment of Erectile Dysfunction (ED) from March 1st, 2024. Eroxon, which was launched in the UK in March 2023, is also available without a doctor's prescription. James Barder, CEO of Futura, expressed that this milestone is a significant step in improving the availability of Eroxon, providing access by prescription for men with ED as well as over the counter.

Futura Medical PLC is the developer of innovative sexual health products, with a core focus on research, development, and commercialization of topically delivered gel formulations in sexual health products. Eroxon, the company's clinically proven lead product, is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addressing significant unmet needs in the ED market. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in major consumer markets, including Haleon in the US and Cooper Consumer Health in Europe. Eroxon has been nominated for several healthcare industry awards and has won two to date. This development marks a significant advancement for Futura Medical PLC and its commitment to providing innovative solutions for sexual health.